Systemic interleukin 10 administration inhibits brain tumor necrosis factor production in mice

Interleukin 10 is an antiinflammatory cytokine and inhibits the production of tumor necrosis factor. We have previously found that intracerebroventricular (i.c.v.) administration of recombinant human interleukin 10 inhibits brain tumor necrosis factor production induced by an i.c.v. injection of lip...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 1997-10, Vol.336 (2-3), p.197-202
Main Authors: DI SANTO, E, ADAMI, M, BERTORELLI, R, GHEZZI, P
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Blood - drug effects
Blood - metabolism
Bones, joints and connective tissue. Antiinflammatory agents
Brain - drug effects
Brain - metabolism
Cell Line
Humans
In Vitro Techniques
Interleukin-10 - administration & dosage
Interleukin-10 - blood
Interleukin-10 - pharmacology
Lipopolysaccharides
Male
Medical sciences
Mice
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Tumor Necrosis Factor-alpha - biosynthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin 10 is an antiinflammatory cytokine and inhibits the production of tumor necrosis factor. We have previously found that intracerebroventricular (i.c.v.) administration of recombinant human interleukin 10 inhibits brain tumor necrosis factor production induced by an i.c.v. injection of lipopolysaccharide in mice. In view of its possible pharmacological use, we have now studied whether interleukin 10 administered peripherally could inhibit brain tumor necrosis factor production. Mice were injected with recombinant human interleukin 10 (20 microg/mouse, i.v.) 10 min-24 h before lipopolysaccharide (2.5 microg, i.c.v.). Tumor necrosis factor was measured, using a bioassay, in brain homogenates 90 min after lipopolysaccharide. Recombinant human interleukin 10 administered i.v. between 10 min and 6 h before lipopolysaccharide markedly inhibited brain tumor necrosis factor production. We also measured the production of tumor necrosis factor by whole blood of these mice, and it was also markedly inhibited by recombinant human interleukin 10 treatment. In conclusion, systemic recombinant human interleukin 10 administration inhibits brain tumor necrosis factor production. suggesting its usefulness in tumor necrosis factor-mediated pathologies of the central nervous system.
ISSN:0014-2999
1879-0712
DOI:10.1016/s0014-2999(97)01225-9